[go: up one dir, main page]

MX2012003170A - Compuestos heterociclicos antivirales. - Google Patents

Compuestos heterociclicos antivirales.

Info

Publication number
MX2012003170A
MX2012003170A MX2012003170A MX2012003170A MX2012003170A MX 2012003170 A MX2012003170 A MX 2012003170A MX 2012003170 A MX2012003170 A MX 2012003170A MX 2012003170 A MX2012003170 A MX 2012003170A MX 2012003170 A MX2012003170 A MX 2012003170A
Authority
MX
Mexico
Prior art keywords
antiviral compounds
heterocyclic antiviral
heterocyclic
compounds
hepatitis
Prior art date
Application number
MX2012003170A
Other languages
English (en)
Inventor
Vicente Fidalgo Javier De
Jim Li
Ryan Craig Schoenfeld
Francisco Xavier Talamas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012003170A publication Critical patent/MX2012003170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula I, en la que R1, R2, R3, R4, y R5 tienen los significados aquí definidos, son inhibidores de la polimerasa NS5b del virus de la hepatitis C. Se describen también composiciones y métodos para tratar una infección del HCV y para inhibir la replicación del HCV. (ver fórmula (I)).
MX2012003170A 2009-09-21 2010-09-17 Compuestos heterociclicos antivirales. MX2012003170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24428709P 2009-09-21 2009-09-21
PCT/EP2010/063660 WO2011033045A1 (en) 2009-09-21 2010-09-17 Heterocyclic antiviral compounds

Publications (1)

Publication Number Publication Date
MX2012003170A true MX2012003170A (es) 2012-04-11

Family

ID=43217210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003170A MX2012003170A (es) 2009-09-21 2010-09-17 Compuestos heterociclicos antivirales.

Country Status (12)

Country Link
US (1) US8063072B2 (es)
EP (1) EP2480533A1 (es)
JP (1) JP2013505218A (es)
KR (1) KR20120059626A (es)
CN (1) CN102498100A (es)
AR (1) AR078397A1 (es)
AU (1) AU2010297290A1 (es)
BR (1) BR112012005616A2 (es)
CA (1) CA2768924A1 (es)
MX (1) MX2012003170A (es)
TW (1) TW201116520A (es)
WO (1) WO2011033045A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324249B2 (en) * 2008-08-01 2012-12-04 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
WO2010072598A1 (en) * 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US10752611B2 (en) 2009-02-27 2020-08-25 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
EP2797416B1 (en) 2011-12-28 2017-08-09 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
KR102293060B1 (ko) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
TW201536789A (zh) 2013-07-29 2015-10-01 Enanta Pharm Inc Ｃ型肝炎病毒抑制劑
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015120133A1 (en) 2014-02-07 2015-08-13 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
BR112018011272A2 (pt) 2015-12-04 2018-11-21 Global Blood Therapeutics Inc regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CN110724091B (zh) * 2019-12-04 2022-03-11 阿里生物新材料（常州）有限公司 一种6-（二氟甲基）-2-羟基吡啶-3-磺酰氯的合成方法
CN112876409A (zh) * 2021-01-20 2021-06-01 都创(上海)医药科技股份有限公司 一种2-(5-溴-6-甲氧基吡啶-2-基)乙腈及其衍生物的合成方法
CN117324042B (zh) * 2023-09-28 2025-08-19 中国科学院长春应用化学研究所 一种用于酚类衍生物脱氧的催化体系及温和高效的脱氧方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047833A1 (en) 1999-12-24 2001-07-05 Asahi Glass Company, Limited Silicon nitride filter and method of manufacture thereof
EP1292310A1 (en) 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
US6899700B2 (en) 2001-08-29 2005-05-31 Kimberly-Clark Worldwide, Inc. Therapeutic agent delivery tampon
AU2002359320A1 (en) 2001-10-29 2003-05-12 Smithkline Beecham Corporation Novel anit-infectives
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
WO2003099801A1 (en) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
KR20050065670A (ko) 2002-11-01 2005-06-29 아보트 러보러터리즈 항감염제
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
WO2004052313A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
WO2004052312A2 (en) 2002-12-11 2004-06-24 Smithkline Beecham Corporation Anti-infectives
AU2003297235A1 (en) 2002-12-17 2004-07-22 Smithkline Beecham Corporation Anti-infectives
WO2005000818A1 (en) * 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005019191A2 (en) 2003-08-25 2005-03-03 Abbott Laboratories 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
JP4624419B2 (ja) 2004-08-23 2011-02-02 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス性へテロ環化合物
US7576080B2 (en) 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
JP2008540370A (ja) 2005-05-04 2008-11-20 エフ．ホフマン−ラ ロシュ アーゲー ヘテロ環式抗ウイルス化合物
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
TW200911807A (en) 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
TW200918536A (en) 2007-08-29 2009-05-01 Schering Corp Tetracyclic indole derivatives and methods of use thereof
BRPI0816116A2 (pt) 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
RU2542099C2 (ru) 2007-09-17 2015-02-20 Эббви Бахамаз Лтд. N-фенил-диоксо-гидропиримидины, используемые в качестве ингибитора вируса гепатита с (hcv)
EP2725015A1 (en) 2007-09-17 2014-04-30 AbbVie Bahamas Ltd. Uracil or thymine derivative for treating hepatitis c
ES2523864T3 (es) 2007-09-17 2014-12-02 Abbvie Bahamas Ltd. Pirimidinas antiinfecciosas y usos de las mismas
CN102317285A (zh) 2007-11-16 2012-01-11 先灵公司 3-氨基磺酰基取代的吲哚衍生物及其使用方法
MX2010005356A (es) 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
AU2009273327A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2334662A1 (en) 2008-09-26 2011-06-22 F. Hoffmann-La Roche AG Pyrine or pyrazine derivatives for treating hcv
AU2009309813A1 (en) 2008-10-30 2010-05-06 F. Hoffmann-La Roche Ag Heterocyclic antiviral arylpyridone derivatives
WO2010072598A1 (en) 2008-12-22 2010-07-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
SG10201400957UA (en) 2009-03-25 2014-09-26 Abbott Lab Antiviral Compounds And Uses Thereof
JP5571167B2 (ja) 2009-03-25 2014-08-13 アッヴィ・インコーポレイテッド 抗ウイルス組成物およびこの使用

Also Published As

Publication number Publication date
AU2010297290A1 (en) 2012-03-15
JP2013505218A (ja) 2013-02-14
EP2480533A1 (en) 2012-08-01
BR112012005616A2 (pt) 2016-06-21
TW201116520A (en) 2011-05-16
CN102498100A (zh) 2012-06-13
CA2768924A1 (en) 2011-03-24
KR20120059626A (ko) 2012-06-08
US8063072B2 (en) 2011-11-22
WO2011033045A1 (en) 2011-03-24
US20110070189A1 (en) 2011-03-24
AR078397A1 (es) 2011-11-02

Similar Documents

Publication Publication Date Title
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2010004623A (es) Compuestos heterociclicos antiviricos.
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
MY157435A (en) Heterocyclic antiviral compounds
TW200745151A (en) Antiviral nucleosides
MX2009008872A (es) Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c.
TW200720285A (en) Nucleoside compounds for treating viral infections
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2009004888A (es) Inhibidores del virus de la hepatitis c.
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
WO2009069095A3 (en) Antiviral nucleoside compounds
EP2542545A4 (en) INHIBITORS OF HEPATITIS C-VIRUS NS5B POLYMERASE
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
PL1987038T3 (pl) Inhibitory HCV NS5B
TW200724540A (en) Heterocyclic antiviral compounds
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
MX2012006513A (es) Compuestos heterociclicos antivirales.
MX2011012541A (es) Compuestos heterociclicos antivirales.
MX2010005226A (es) Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.
MX2011008641A (es) Compuestos heterociclicos antivirales.
MX2011011112A (es) Compuestos antivirales heterociclicos.
WO2012019299A9 (en) Hepatitis c inhibitor compounds
MX2011012240A (es) Compuestos heterociclicos antivirales.
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal